

Department of Consumer Affairs



Prescribing and Furnishing Authority of Naturopathic Doctors Subcommittee Meeting

Thursday, October 24, 2019
1:00 p.m.

TELECONFERENCE SITES

Main Meeting Location:

Department of Consumer Affairs
1625 North Market Blvd., Suite N-220
El Dorado Room
Sacramento, CA 95834

Naturopathic Medicine Committee
Phone: (916) 928-4785

TABLE OF CONTENTS

TAB 1	Agenda
TAB 2	Public Comment for Items Not on Agenda
TAB 3	Possible Recommendations Regarding Prescribing and Furnishing Authority of a Naturopathic Doctor <ul style="list-style-type: none">a) Education and Training Requirementsb) Certification for Drug Furnishing: Basic and Advanced Pharmacologyc) Appropriate Timelines for Grandfathering Clausesd) Exam/Testing Requirements for New License Applicantse) Authority for NDs to Discuss or Recommend Cannabis with Patients
TAB 4	Review/Approval Draft Meeting Minutes <ul style="list-style-type: none">a) May 9, 2019 meetingb) July 18, 2019 meeting
TAB 5	Establish Future Meeting Dates and Locations
TAB 6	Agenda Items for Future Meetings

TAB 1

Agenda



**Subcommittee
Members**

Minna Yoon, ND
Peter Koshland, PharmD
Thomas G. Quinn, MD

NATUROPATHIC MEDICINE COMMITTEE

**PRESCRIBING AND FURNISHING AUTHORITY
OF NATUROPATHIC DOCTORS SUBCOMMITTEE**

AGENDA AND NOTICE OF TELECONFERENCE MEETING

Thursday, October 24, 2019
1:00 p.m. to 2:00 p.m.
(or until the close of business)

Teleconference Locations:
Department of Consumer Affairs
1625 North Market Blvd.
El Dorado Room – Ste. N-220
Sacramento, CA 95834

(No Subcommittee members will be at the Sacramento location;
it is offered as an additional location for staff and the public.)

Sutter East Bay Medical Group
350 30th Street, Suite 411
Oakland, CA 94609

Koshland Pharmacy
301 Folsom St., Suite B
San Francisco, CA 94105

Each teleconference location is accessible to the public and the public will be given an opportunity to address the Subcommittee at each teleconference location.

AGENDA

NOTE: The order of business is subject to change. This meeting will not be webcast.

1. Call to Order and Roll Call / Establishment of Quorum
2. Public Comment for Items Not on Agenda
The Subcommittee may not discuss or take action on any item raised during this public comment section, except to decide whether to place the matter on the agenda of a future meeting. (Gov. Code, §§ 11125, 11125.7(a).)
3. Discussion and Possible Recommendations Regarding Prescribing and Furnishing Authority of Naturopathic Doctors:
 - a. Education and Training Requirements
 - b. Certification for Drug Furnishing: Basic and Advanced pharmacology training and certification
 - c. Appropriate timelines for grandfathering clauses (current NDs working within physician protocols)

- d. What exam or testing should be required for new license applicants (NPLEX Pharmacology Elective Exam)
 - e. Authority for NDs to discuss or recommend cannabis with patients
 - f. Medical Errors in Prescribing or Administering by NDs
4. Review and Possible Approval of Prescribing and Furnishing Authority of Naturopathic Doctors Subcommittee Meeting Minutes
 - a. May 9, 2019 Meeting
 - b. July 18, 2019 Meeting
 5. Establish Future Meeting Dates and Locations
 6. Agenda Items for Future Meetings
 7. Adjournment

For further information about this meeting, please contact Rebecca Mitchell at (916) 928-4785 or in writing at 1300 National Drive, Suite 150, Sacramento, CA 95834-1991. This notice and agenda, as well as any available meeting materials, can be accessed at www.naturopathic.ca.gov.

Discussion may be taken on any item on the agenda. The time and order of agenda items are approximate and subject to change at the discretion of the Subcommittee Chair to facilitate the effective transaction of business.

In accordance with the Bagley-Keene Open Meeting Act, all meetings of the Subcommittee, including the teleconference sites, are open to the public. Government Code section 11125.7 provides the opportunity for the public to address each agenda item during discussion or consideration by the Subcommittee prior to the Subcommittee taking any action on said item. Members of the public will be provided appropriate opportunities to comment on any issue before the Subcommittee, but the Subcommittee Chair may, at his or her discretion, apportion available time among those who wish to speak. Individuals may appear before the Subcommittee to discuss items not on the agenda; however, the Subcommittee can neither discuss nor take official action on these items at the time of the same meeting. (Gov. Code, §§ 11125, 11125.7(a).)




Subcommittee meetings are held in barrier free facilities that are accessible to those with physical disabilities in accordance with the Americans with Disabilities Act (ADA). If you are a person with a disability requiring disability-related modifications or accommodations to participate in the meeting, including auxiliary aids or services, please contact Rebecca Mitchell, ADA Liaison, at (916) 928-4785 or via email at Rebecca.Mitchell@dca.ca.gov or send a written request to the Naturopathic Medicine Committee's office at 1300 National Drive, Suite 150, Sacramento, CA 95834-1991. Providing your request to our office at least five (5) business days before the meeting will help ensure availability of the requested accommodation(s). You may also dial a voice TTY/TDD Communications Assistant at (800) 322-1700 or 7-1-1.

TAB 2

Public Comments

**Name of Public Providing
Comment**

Comment Presented



TAB 3

Discussion and Possible Recommendations
Regarding Prescribing and Furnishing of a
Naturopathic Doctor

A. Education and Training Requirements

B. Certification for Drug Furnishing:
Basic and Advanced Pharmacology

System	Name	Purpose and Drug Class	
Cardiovascular	amiodarone	anti-arrhythmic-adrenergic antagonist	
Cardiovascular	amlodipine	anti-arrhythmic-Ca channel blocker	
Cardiovascular	atenolol	antihypertensive-beta blocker	
Cardiovascular	atorvastatin	cholesterol lowering-statin	
Cardiovascular	carvedilol	antihypertensive-alpha and beta blocker	
Cardiovascular	clonidine	antihypertensive- α -2 adrenergic agonist	
Cardiovascular	colesevelam	bile acid sequestrant	
Cardiovascular	digoxin	cardiacglycoside	
Cardiovascular	diltiazem	anti-arrhythmic-Ca channel blocker	
Cardiovascular	ezetimibe	cholesterol lowering-nonstatin	
Cardiovascular	flecainide	anti-arrhythmic-sodium channel blocker	
Cardiovascular	furosemide	antihypertensive-loop diuretic	
Cardiovascular	gemfibrozil	lipid lowering-fibrate	
Cardiovascular	hydralazine	antihypertensive-hydrazinophthalazine	
Cardiovascular	hydrochlorothiazide	diuretic	
Cardiovascular	mononitrate	angina-nitrate	
Cardiovascular	lisinopril	antihypertensive-ACE inhibitor	
Cardiovascular	losartan	antihypertensive-angiotensin II antagonist	
Cardiovascular	nitroglycerin	angina-nitrate	
Cardiovascular	pentoxifylline	anti-claudication-methylated xanthine derivatives	
Cardiovascular	propranolol	antihypertensive-beta blocker, non-selective	
Cardiovascular	spironolactone	antihypertensive-diuretic	
Cardiovascular	triamterene	antihypertensive-diuretic (non-sulpha)	
Cardiovascular	verapamil	anti-arrhythmic-Ca channel blocker	
Endocrine	bromocriptine	antiparkinsonism-dopamine agonist	

System	Name	Purpose and Drug Class	
Endocrine	calcitonin	lowers serum calcium	
Endocrine	canagliflozin	hypoglycemic agent-flozin (SGLT-2 inhibitor)	
Endocrine	clomiphene	SERM - for infertility	
Endocrine	desmopressin	antidiuretic-synthetic ADH for D	
Endocrine	DHEA	anaboloic steroid, androgen	
Endocrine	drospirenone/ethinyl estradiol	anti-androgen - progestin	
Endocrine	estradiol	estrogen replacement	
Endocrine	estriol	estrogen replacement	
Endocrine	fludrocortisone	synthetic corticosteroid	
Endocrine	glucagon	hyperglycemic agent	
Endocrine	glyburide	hypoglycemic agent-sulfonylurea	
Endocrine	human chorionic gonadotropin	fertility-stimulate ovulation	
Endocrine	hydrocortisone	anti-inflammatory/anti-pruritic	
Endocrine	insulin-glargine	hypoglycemic agent - long-acting	
Endocrine	insulin-lispro	hypoglycemic agent - fast-acting	
Endocrine	insulin-regular	hypoglycemic agent	
Endocrine	levonorgestrel	contraceptive-progestin IUD	
Endocrine	levothyroxine	hypothyroid	
Endocrine	liothyronine	hypothyroid	
Endocrine	liraglutide	hypoglycemic agentic - GLP-1 receptor agonist	
Endocrine	medroxyprogesterone	progestin	
Endocrine	megestrol acetate	antineoplastic and appetite stimulant	
Endocrine	metformin	hypoglycemic agent-biguanide	
Endocrine	methimazole	hyperthyroid	
Endocrine	norelgestromin/ethinyl estradiol-patch	contraceptive-transdermal	
Endocrine	norethindrone	contraceptive progestin	
Endocrine	octreotide	somatostatin mimetic	
Endocrine	pioglitazone	hypoglycemic agent-thiazolidinedione	
Endocrine	progesterone-oral micronized	progesterone replacement	
Endocrine	propylthiouracil	hyperthyroid	

System	Name	Purpose and Drug Class	
Endocrine	sitagliptin	hypoglycemic agent - DPP-4 inhibitor	
Endocrine	somatropin	rhGH	
Endocrine	testosterone	anabolic steroid	
Endocrine	thyroid-USP	hypothyroid	
Blood and Lymph	clopidogrel	anticoagulant-inhibits platelet aggregation	
Blood and Lymph	dabigatran	anticoagulant- direct thrombin inhibitor	
Blood and Lymph	enoxaparin	anticoagulant-factor Xa inhibitor	
Blood and Lymph	epoetin alfa	anemia-human erythropoietin	
Blood and Lymph	heparin	anticoagulant-factor Xa inhibitor	
Blood and Lymph	potassium chloride	potassium increasing	
Blood and Lymph	rivaroxaban		
Blood and Lymph	vitamin K1	coagulation co-factor	
Blood and Lymph	warfarin	anticoagulant-vit K agonist	
Dermatological	5-fluorouracil		
Dermatological	calicipotriol	antipsoriatic-topical	
Dermatological	clobetasol propionate	corticosteroid-topical	
Dermatological	isotretinoin	acne-retinoid	
Dermatological	minocycline	antibiotic-tetracycline	
Dermatological	mupirocin	antibiotic-monoxycarbolic acid	
Dermatological	selenium disulfide	antifungal/antipsoriatic	
Dermatological	tacrolimus	immunosuppressant-eczema	
Dermatological	tretinoin	acne - topical retinoid	
Eye, Ear, Nose	cromolyn sodium	stabilizer	
Eye, Ear, Nose	ophthalmic	inflammatory	
Eye, Ear, Nose	gentamycin drops	antibiotic-aminoglycoside	
Eye, Ear, Nose	latanoprost	glaucoma	
Eye, Ear, Nose	meclizine-OTC	antiemetic-patch	
Eye, Ear, Nose	neomycin/polymixinB/hydrocortisone	corticosteroid and antibiotic-otic use	

System	Name	Purpose and Drug Class	
Eye, Ear, Nose	nepafenac	NSAID-ophthalmic	
Eye, Ear, Nose	ophthalmic	conjunctivitis-antihistamine	
Eye, Ear, Nose	pilocarpine	glaucoma- parasympathomimetic	
Eye, Ear, Nose	timolol	glaucoma	
Gastro/Hepatic	budesonide-oral	corticosteroid	
Gastro/Hepatic	diphenoxylate/atropine	diarrhea	
Gastro/Hepatic	esomeprazole	proton pump inhibitor	
Gastro/Hepatic	hyoscyamine	antiemetic/antispasmodic- tropaine alkaloid	
Gastro/Hepatic	mesalazine (mesalamine)	anti-inflammatory- aminosalicylate	
Gastro/Hepatic	metoclopramide	antagonist	
Gastro/Hepatic	ondansetron	antiemetic- SS 5-HT3 antagonist	
Gastro/Hepatic	promethazine	antiemetic-antihistamine	
Gastro/Hepatic	rifaximin	antibiotic-GI specific	
Gastro/Hepatic	scopolamine	anti-emetic/antispasmodic - tropaine alkaloid	
Gastro/Hepatic	sulfasalazine	anti-inflammatory- aminosalicylate	
Gastro/Hepatic	ursodeoxycholic acid	cholesterol lowering -non- statin	
Genitourinary	alprostadil	vasodilator-erectile dysfunction	
Genitourinary	bethanechol	incontinence/neurogenic bladder	
Genitourinary	doxazosin	urinary retention- α 1 receptor antagonist	
Genitourinary	finasteride	BPH-5 α -reductase inhibitor	
Genitourinary	nitrofurantoin	antibiotic-concentrated in the urine	
Genitourinary	oxybutynin	incontinence-antimuscarinic	
Genitourinary	sildenafil	erectile dysfunction-PDE5 inhibitor	
Genitourinary	solifenacin	incontinence (urge)- antimuscarinic	
Genitourinary	tamsulosin	urinary retention- α 1 receptor antagonist	

System	Name	Purpose and Drug Class	
Genitourinary	terazosin	BPH- selective α -1 antagonist	
Genitourinary	tolterodine	incontinence-antimuscarinic	
Musculoskeletal	alendronate	osteoporosis-bisphosphonate	
Musculoskeletal	allopurinol	uric acid lowering	
Musculoskeletal	baclofen	muscle relaxant-CNS depressant	
Musculoskeletal	botulinum toxin	spasmolytic	
Musculoskeletal	colchicine	uric acid lowering	
Musculoskeletal	cyclobenzaprine	depressant	
Musculoskeletal	denosumab	monoclonal antibody for osteoporosis	
Musculoskeletal	diclofenac-gel	NSAID-gel	
Musculoskeletal	fingolimod	immunomodulator-for MS	
Musculoskeletal	glatiramer acetate	immunomodulator-for MS	
Musculoskeletal	raloxifene	osteoporosis-SERM	
Neurological	benztropine	parkinsonism-anticholinergic, antihistamine	
Neurological	bupivacaine	local anesthetic-amide	
Neurological	buprenorphine	opiate-partial agonist	
Neurological	gabapentin	antiepileptic/analgesic-GABA analog	
Neurological	lamotrigine	antiepileptic/mood stabilizer	
Neurological	levodopa/carbidopa	parkinsonism-dopamine precursor	
Neurological	lidocaine	local anesthetic-amide	
Neurological	modafinil	sympathomimetic (schedule IV)	
Neurological	nicotine-patch	smoking cessation	
Neurological	phenytoin	antiepileptic	
Neurological	pramipexole	agonist	
Neurological	pregabalin	antiepileptic/anxiolytic-GABA analog	
Neurological	procaine	local anesthetic-ester	
Neurological	sumatriptan	migraine-SS receptor agonist	

System	Name	Purpose and Drug Class	
Neurological	topiramate	antiepileptic-carbonic anhydrase inhibitor	
Neurological	valproate (divalproex)	antiepileptic	
Neurological	varenicline	smoking cessation	
Neurological	zolpidem	sedative-hypnotic	
Respiratory	albuterol (salbutamol)-inhaler	bronchodilator- SABA -b2 agonist	
Respiratory	beclomethasone	corticosteroid-asthma	
Respiratory	benzonatate	antitussive	
Respiratory	epinephrine/adrenalin	anaphylaxis- catecholamine	
Respiratory	fluticasone	corticosteroid-asthma	
Respiratory	ipratropium bromide	bronchodilator-anticholinergic (muscarinic antagonist)	
Respiratory	montelukast	asthma-leukotriene receptor antagonist (LTRA)	
Respiratory	salmeterol	agonist	
Respiratory	tiotropium bromide	bronchodilator-anticholinergic (muscarinic antagonist)	
Psychiatric & Cognitive	alprazolam	anxiolytic-benzodiazepine	
Psychiatric & Cognitive	amitriptyline	antidepressant-tricyclic	
Psychiatric & Cognitive	aripiprazole	antipsychotic-atypical	
Psychiatric & Cognitive	atomoxetine	ADHD-NeRI	
Psychiatric & Cognitive	bupropion	antidepressant-NDRI	
Psychiatric & Cognitive	clozapine	antipsychotic	
Psychiatric & Cognitive	dextroamphetamine	ADHD/narcolepsy-amphetamine	
Psychiatric & Cognitive	diazepam	anxiolytic-benzodiazepine	
Psychiatric & Cognitive	donepezil	dementia-acetylcholinesterase inhibitor	
Psychiatric & Cognitive	duloxetine	antidepressant-SNRI	
Psychiatric & Cognitive	escitalopram	antidepressant-SSRI	

System	Name	Purpose and Drug Class	
Psychiatric & Cognitive	fluoxetine	antidepressant-SSRI	
Psychiatric & Cognitive	haloperidol	antipsychotic- butyrophenone	
Psychiatric & Cognitive	hydroxyzine	anxiolytic/antipsychotic	
Psychiatric & Cognitive	lithium	mood stabilizer	
Psychiatric & Cognitive	memantine	dementia-NMDA receptor antagonist	
Psychiatric & Cognitive	methylphenidate	ADHD-phenethylamine	
Psychiatric & Cognitive	mirtazapine	antidepressant-NaSSA Tetracyclic	
Psychiatric & Cognitive	paroxetine	antidepressant-SSRI	
Psychiatric & Cognitive	phenelzine	antidepressant/anxiolytic-MAOI	
Psychiatric & Cognitive	quetiapine	antipsychotic	
Psychiatric & Cognitive	rivastigmine	dementia-acetylcholinesterase inhibitor	
Psychiatric & Cognitive	trazodone	antidepressant-SSRI/ anxiolytic-hypnotic	
Psychiatric & Cognitive	venlafaxine	antidepressant-SNRI	
Pain Management	cannabis	analgesic/appetite stimulant (schedule I)	
Pain Management	celecoxib	cox-2 inhibitor	
Pain Management	cocaine	anesthetic/recreational drug	
Pain Management	codeine	analgesic-opioid	
Pain Management	fentanyl	analgesic-opioid	
Pain Management	hydrocodone	antitussive	
Pain Management	indomethacin	NSAID	
Pain Management	ketamine	anesthetic	
Pain Management	ketorolac	NSAID	
Pain Management	methadone	analgesic-opioid/tx opioid addiction	
Pain Management	naloxone	opioid antagonist-treats overdose	
Pain Management	naltrexone	opioid antagonist-treats etoh withdrawal	

System	Name	Purpose and Drug Class	
Pain Management	oxycodone	analgesic-opioid	
Pain Management	tramadol	analgesic-opioid	
Anti-Microbial	acyclovir	antiviral-nucleic acid analog	
Anti-Microbial	adefovir	antiviral-acyclic nucleotide analog	
Anti-Microbial	albendazole	antihelminthic	
Anti-Microbial	amoxicillin	antibiotic-beta-lactam	
Anti-Microbial	amoxicillin/ clavulanate	antibiotic	
Anti-Microbial	azithromycin	antibiotic-macrolide	
Anti-Microbial	cefdinir	antibiotic-cephlasporin	
Anti-Microbial	ceftriaxone	antibiotic-cephlasporin	
Anti-Microbial	cephalexin	antibiotic-cephlasporin	
Anti-Microbial	ciprofloxacin	antibiotic-fluoroquinolone	
Anti-Microbial	clarithromycin	antibiotic-macrolide	
Anti-Microbial	clindamycin	antibiotic-lincosamide	
Anti-Microbial	doxycycline	antibiotic-tetracycline	
Anti-Microbial	erythromycin	antibiotic-macrolide	
Anti-Microbial	fluconazole	antifungal-azole	
Anti-Microbial	isoniazid	antibiotic-mycobacteria (isonicotinylhydrazide)	
Anti-Microbial	ivermectin	antiparasitic	
Anti-Microbial	ketoconazole	antifungal-azole	
Anti-Microbial	levofloxacin	antibiotic-fluoroquinolone	
Anti-Microbial	metronidazole	antibiotics- 5-nitroimidazole	
Anti-Microbial	oseltamivir	antiviral-neuraminidase inhibitor	
Anti-Microbial	penicillin VK	antibiotic-1st generation penicillin	
Anti-Microbial	permethrin	pediculoside-pyrethroid	
Anti-Microbial	rifampin (rifampicin)	antibiotic-mycobacteria	
Anti-Microbial	sulfamethoxazole/ trimethoprim	antibiotic-sulfonamide	
Anti-Microbial	terbinafine	antifungal-allylamine	
Anti-Microbial	valacyclovir	antiviral-guanosine analog	

System	Name	Purpose and Drug Class	
Anti-Microbial	vancomycin	antibiotic-glycopeptide	
Anti-Microbial	zidovudine (AZT)	antiviral-nucleoside analog (reverse-transcriptase inhibitor)	
Vaccine	cholera vaccine	vaccination	
Vaccine	influenzae (Hib) vaccine	vaccination	
Vaccine	HepA/B vaccine	vaccination	
Vaccine	HPV quad vaccine	vaccination	
Vaccine	influenza vaccine	vaccination	
Vaccine	meningococcal vaccine	vaccination	
Vaccine	pneumococcal polyvalent vaccine	vaccination	
Vaccine	Tdap and Dtap vaccine	vaccination	
Vaccine	varicella vaccine and zoster vaccine	vaccination	
Chemo/Chel/Imm	adalimumab	immunosuppressant- TNF inhibitor	
Chemo/Chel/Imm	anastrozole	aromatase inhibitor BPH - non-steroidal	
Chemo/Chel/Imm	bicalutamide	antiandrogen (NSAA)	
Chemo/Chel/Imm	cisplatin	antineoplastic-platinum containing	
Chemo/Chel/Imm	cyclophosphamide	antineoplastic-alkylating agent	
Chemo/Chel/Imm	cyclosporine	immunosuppressant	
Chemo/Chel/Imm	dexamethasone	corticosteroid	
Chemo/Chel/Imm	DMPS	chelating agent	
Chemo/Chel/Imm	DMSA	chelating agent	
Chemo/Chel/Imm	doxorubicin	antineoplastic-anthracyclines	
Chemo/Chel/Imm	EDTA	chelating agent	
Chemo/Chel/Imm	etanercept	arthritis (rheumatoid and psoriatic)-TNF inhibitor	
Chemo/Chel/Imm	hydroxychloroquine	anti-inflammatory/ immunosuppressant	
Chemo/Chel/Imm	imiquimod	immunomodulator	
Chemo/Chel/Imm	infliximab	monoclonal antibody against TNF- α	
Chemo/Chel/Imm	interferon-beta	immunosuppressant MS	
Chemo/Chel/Imm	interferon alpha	immunosuppressant, antiviral hepatitis	

System	Name	Purpose and Drug Class	
Chemo/Chel/Imm	leuprolide	GnRH analogue	
Chemo/Chel/Imm	methotrexate	antimetabolite	i
Chemo/Chel/Imm	methylprednisolone	corticosteroid	
Chemo/Chel/Imm	paclitaxel	antineoplastic-taxane	
Chemo/Chel/Imm	penicillamine	chelating agent-copper, immunosuppressor	
Chemo/Chel/Imm	prednisolone	corticosteroid	
Chemo/Chel/Imm	prednisone	corticosteroid	
Chemo/Chel/Imm	tamoxifen	antineoplastic-SERM	
Chemo/Chel/Imm	thalidomide	immunosuppressant	
Chemo/Chel/Imm	tofacitinib	JAK inhibitor	
Chemo/Chel/Imm	trastuzumab	monoclonal antibody against HER2 receptors	
Chemo/Chel/Imm	triamcinolone	corticosteroid	
Chemo/Chel/Imm	vinblastine	antineoplastic-inhibits mitosis	

I

C. Appropriate Time Lines for
Grandfathering Clauses

D. Exam/Testing Requirements for New License Applicants

E. Authority for NDs to Discuss/Recommend Cannabis
with patients

TAB 4

Review/Approval of Draft Meeting Minutes

A. May 9, 2019 Draft Meeting Minutes



**NATUROPATHIC MEDICINE COMMITTEE
PRESCRIBING AND FURNISHING AUTHORITY
OF NATUROPATHIC DOCTORS SUBCOMMITTEE
MEETING MINUTES**

May 9, 2019

DRAFT

**MEMBERS
PRESENT:** Minna Yoon, ND, Chair
Peter Koshland, PharmD
Thomas G. Quinn, MD

**MEMBERS
ABSENT:** None

**STAFF
PRESENT:** Rebecca Mitchell, Executive Officer (EO)
Sabina Knight, Esq., Legal Counsel
Salwa Bojak, Esq., Legal Counsel

**MEMBERS OF
THE AUDIENCE:** None

Agenda Item 1 Call to Order/Roll Call/Establishment of a Quorum

Minna Yoon, ND, Chair, Prescribing and Furnishing Authority of Naturopathic Doctors Subcommittee of the Naturopathic Medicine Committee (NMC), called the meeting of the Prescribing and Furnishing Authority of Naturopathic Doctors Subcommittee to order on May 9, 2019, at 12:03 p.m. A quorum was present and due notice was provided to all interested parties.

Agenda Item 2 Public Comment for Items Not on Agenda

There were no public comments for any items not on the agenda to discuss.

Agenda Item 3 Discussion and Possible Recommendations Regarding Prescribing and Furnishing Authority of a Naturopathic Doctor:

Dr. Yoon introduced the subcommittee. Rebecca Mitchell, Executive Officer, Naturopathic Medicine Committee reiterated the purpose of the subcommittee is to review education and training of naturopathic doctors (NDs), review national standards

for NDs and make a recommendation to the full Committee on potential amendments to the Naturopathic Doctors Act (Act).

Items that will be reviewed by the subcommittee members include: the education and training of accredited naturopathic schools, current standards for drug formularies in other states, and the scope, safety and efficacy of naturopathic medicine on a national level.

Ms. Mitchell also reported that resources to assist in the review process were included in the meeting materials. These materials included:

- Original 2007 Findings and Recommendations Regarding the Prescribing and Furnishing Authority of a Naturopathic Doctor – presented to the California State Legislature on 1/1/2007.
- Information on the national education requirements for becoming licensed NDs.
- Association of Accredited Naturopathic Medical Colleges (AANMC) Core Competencies of the Graduating Naturopathic Student.
- Copy of Business and Professions Code section 3640.8 which outline the current requirements to become certified to perform IV Therapy with the Committee.
- Drug Formulary of neighboring RAs (Oregon).
- Scope of Practice for all naturopathic medicine regulating authorities (RAs). This shows that 14 other RA states, including neighboring states of Oregon, Washington, and Colorado, have a full scope formulary for legend drugs and scheduled drugs III through V.
- Distribution of Licensee Populations and Medically Under-served Areas/Populations, which shows 15% of licensed NDs in CA work with medically under-served populations (MUP) and 58% of licensed NDs in CA work in medically under-served areas (MUA). This helps bridge the gap for healthcare barriers but could do a lot more if NDs in CA were able to practice-as-trained and work at the full primary care practitioner level.

a. *Education and Training*

EO Rebecca Mitchell, reported information on the education and training stating that a licensed ND attends a four-year, graduate-level naturopathic medical school and is educated in all of the same basic sciences as an allopathic/osteopathic (MD/DO) physician, but also studies holistic and nontoxic approaches to therapy with a strong emphasis on disease prevention and optimizing wellness. In addition, to a standard medical curriculum, the naturopathic physician (ND) also studies clinical nutrition, homeopathic medicine, botanical medicine, psychology, and counseling. An ND takes rigorous

professional board exams so that he or she may be licensed by a state or jurisdiction as a primary care general practice physician.

The American Association of Naturopathic Medical Colleges (AANMC) was established in February 2001 to propel and foster the naturopathic medical profession by actively supporting the academic efforts of accredited and recognized schools of naturopathic medicine. AANMC offers seven (7) accredited naturopathic medical programs and eight (8) campus locations in North America.

The North American Board of Naturopathic Examiners (NABNE) is an independent, nonprofit organization formed as a service to the naturopathic profession and the agencies that license/register naturopathic physicians. NABNE serves regulating authorities by qualifying applicants to take the Naturopathic Physicians Licensing Examination (NPLEX). All license applicants must pass both parts of the NPLEX exam to meet licensing requirements in any of the regulating states.

Dr. Koshland discussed the possibility of having advanced pharmacology training for licensees who practice in specialty fields such as oncology. He suggests that we have an advanced furnishing for those types of drug classifications that are currently excluded (chemotherapeutic drugs). As there are many NDs who currently work in cancer treatment centers, we should not just exclude them altogether. He would also like to see the competency standards for pharmacology of NDs, suggested to get this information from the national board examination entity.

b. Consultant Findings: Prescribing Rights of Naturopathic Doctors from other States

Per data collected from all naturopathic medicine regulating authorities (RAs), 14 of the 22 RA states; including neighboring states of Oregon, Washington, and Colorado, have a full scope when it comes to prescribing or furnishing legend drugs independently, without supervising physician oversight.

California consumers are complaining to the Committee that it is not reasonable that they cannot get the same naturopathic medical care in California that they get in neighboring states.

c. Current Formularies in California

Copies of two current reports issued by the prior Formulary subcommittee (2015) were provided to the current subcommittee. These reports echoed the original recommendations provided in the 2007 report. Similar recommendations were provided in the 1/27/2014 Formulary Subcommittee Report to the Naturopathic Medicine Committee, along with an addendum to the 2014 report issued on 02/23/2015.

The recommendation in short was to eliminate physician oversight. Furthermore, it was recommended that NDs should independently be allowed to prescribe all legend drugs and scheduled drugs 3-5, with the exclusion of schedule 1 and 2 drugs.

EO Mitchell made suggestions that the subcommittee review whether there should be timelines for NDs working under physician protocol when coming up with independent prescribing. For example: a licensee who has prescribed legend drugs and schedules III through V under a physician protocol for a minimum of 5 years without incident, should then be granted independent prescribing ability. For those who are applying for licensure would be required to pass the NPLEX Pharmacology Exam.

Additionally, it was discussed that formularies be updated to be exclusionary based on drug classifications which would be very easy to upkeep moving forward.

Lastly, Dr. Yoon would like to include a recommendation for the ability to discuss cannabis with their patients now that it is able to be used both medically and recreationally by California consumers. Cannabis recommendations should be allowed by NDs as well since they receive education and training on the subject matter in naturopathic colleges.

d. Distribution of Licensee Population and Underserved Areas

Based on current California licensed ND population data pulled from BreZE (Committee's licensing system), 15% of licensed NDs work with medically underserved populations (MUP) and 58% of licensed NDs work in medically underserved areas (MUA).

Agenda Item 4 Establish Timeline for Subcommittee Work and Recommendations

A timeline for the legislative cycle was provided so the subcommittee can work within appropriate timelines. Per staff and legal, the recommendations to the full Committee should be available by the 2019 year-end in order to meet the next legislative session (2020).

Agenda Item 5 Establish Future Meeting Dates and Locations

- 2nd Prescribing and Furnishing Authority of Naturopathic Doctors Subcommittee Meeting – TBD (Mid June)

Agenda Item 6 Agenda Items for Future Meetings

The following are items that were requested to be added to future meetings:

- Confirm legislative calendar dates for 2020 legislative session

- Malpractice Insurance Data for ND (national statistics) – comparisons of ND and allopathic/osteopathic physicians
- Basic and advanced pharmacology training and certification (different levels)
- Timelines for grandfathering current licensees for pharmacology certification
- Exams required for new license applicants – NPLEX Pharmacology Exam
- Authority for NDs to discuss or recommend cannabis with patients

Agenda Item 16 Adjournment

There being no further business or public comment, Dr. Yoon adjourned the meeting at 12:56 p.m.

B. July 18, 2019 Draft Meeting Minutes



**NATUROPATHIC MEDICINE COMMITTEE
PRESCRIBING AND FURNISHING AUTHORITY
OF NATUROPATHIC DOCTORS SUBCOMMITTEE
MEETING MINUTES**

July 18, 2019

DRAFT

**MEMBERS
PRESENT:** Minna Yoon, ND, Chair
Peter Koshland, PharmD
Thomas G. Quinn, MD

**MEMBERS
ABSENT:** None

**STAFF
PRESENT:** Rebecca Mitchell, Executive Officer (EO)
Sabina Knight, Esq., Legal Counsel
Salwa Bojak, Esq., Legal Counsel

**MEMBERS OF
THE AUDIENCE:** None

Agenda Item 1 Call to Order/Roll Call/Establishment of a Quorum

Minna Yoon, ND, Chair, Prescribing and Furnishing Authority of Naturopathic Doctors Subcommittee of the Naturopathic Medicine Committee (NMC), called the meeting of the Prescribing and Furnishing Authority of Naturopathic Doctors Subcommittee to order on July 18, 2019, at 12:00 p.m. A quorum was present and due notice was provided to all interested parties.

Agenda Item 2 Public Comment for Items Not on Agenda

There were no public comments for any items not on the agenda to discuss.

**Agenda Item 3 Discussion and Possible Recommendations Regarding
Prescribing and Furnishing Authority of a Naturopathic
Doctor:**

Dr. Yoon welcomed all participants and requested that the Executive Officer present the information provided within the meeting materials. Rebecca Mitchell, Executive Officer, Naturopathic Medicine Committee provided an overview of the education and training of naturopathic doctors (NDs), including the complete list of drugs that NDs are trained

and tested on upon licensure. The information also provided the national standards for drug formularies for NDs to assist in making informative recommendations to the full Committee on potential amendments to the Naturopathic Doctors Act (Act).

Ms. Mitchell also reported that resources to assist in the review process were included in the meeting materials. These materials included:

- Pharmacology Curriculum for naturopathic schools.
- Naturopathic Physicians Licensing Examinations (NPLEX) Clinical Science Blueprint and Study Guide (includes pharmacology blueprint for NDs).
- CONFIDENTIAL information provided

a. *Education and Training*

Ms. Mitchell included the Pharmacology Curriculum for all of the accredited naturopathic schools along with the NPLEX Pharmacology blueprint and the complete list of drugs that NDs are tested on during the exam.

The list of drugs that NDs are trained and tested on are extremely robust; Dr. Quinn had some concerns that there are certain cardiac classes of drugs that should not be used as they are very dangerous. Dr. Quinn stated that even most primary care physicians should not be utilizing some of the drugs and stated that they may be drugs that NDs should avoid using. Dr. Yoon agreed and stated that in these types of cases, NDs should not use drugs that they are unfamiliar with and should be referring those cardiac cases to a specialist. However, Dr. Yoon advised that a lot of NDs practice in rural areas or underserved areas where they may need to work in tandem with physicians in some cases and have the ability to prescribe a certain drug if needed. She suggested that some care be used when singling out an entire classification if only some drugs within that class should be excluded.

Dr. Koshland stated that the he believes drugs that are needed in primary care practices should be drugs that NDs have within their independent prescriptive rights.

Ms. Mitchell requested that Dr. Quinn list the specific drugs/drug classifications of concern and those can be added to an exclusionary list.

b. *Certification for Drug Furnishing: basic and advanced pharmacology training and certification*

The members discussed and agree that there needs to be advanced training for certain drugs, such as Botox and cosmetic fillers. This will need to be discussed more as the formulary lists are created.

c. *Appropriate time lines for grandfathering clauses (current NDs working within physician protocols)*

The members discussed a grandfathering clause and an appropriate time period that would ensure competency in the independent prescriptive rights for current licensees.

After a thorough discussion, the members felt that in order to ensure that all licensees have met the same requirements for competency in pharmacology, that a grandfathering clause would not be allowed for NDs who want independent prescriptive rights. An exam would need to be passed in order to have independent prescriptive rights.

d. *Exam/Testing requirements for new license applicants*

Dr. Yoon was inquiring what the best way to test the pharmacology knowledge of NDs, Ms. Mitchell suggested that the Committee look into the NPLEX Pharmacology Elective Examination in addition to the NPLEX exam currently used. The Pharmacology Elective Examination is used by other regulatory states and will not be an additional cost to the Committee. The cost to the test taker is minimal.

Dr. Quinn agrees that the Pharmacology Elective Examination would make him feel better about allowing NDs independent prescriptive rights with knowing when and how to refer out when needed to use a drug that is outside of their area of expertise. Dr. Quinn suggested that there needs to be a better way for NDs and physicians to work synergistically together.

All members discussed and agreed to the NPLEX Pharmacology Elective Examination as being a minimum requirement for licensees wanting independent prescriptive rights.

e. *Authority for NDs to discuss or recommend cannabis with patients*

Dr. Yoon requested that NDs have the right to discuss cannabis use with their patients. Now that recreational cannabis has been legalized in California in addition to the heavy use of medically needed cannabis,

Agenda Item 4 Establish Future Meeting Dates and Locations

- Send out poll for meeting dates

Agenda Item 5 Agenda Items for Future Meetings

The following are item(s) that were requested to be added to future meetings:

- Medical errors: morbidity/mortality rates: NDs vs. MD/DOs

Agenda Item 16 Adjournment

There being no further business or public comment, Dr. Yoon adjourned the meeting at 1:03 p.m.

TAB 5

Establish Future Meeting Dates and Locations

Naturopathic Medicine Committee
Establish Future Meeting Dates and Locations

<i>Dates</i>	<i>Locations</i>
4th Quarter FULL NMC Meeting	MON, DEC 9, 2019

NOTE: Please keep costs associated in mind when choosing locations for meetings.

TAB 6

Agenda Items for Future Meetings

